Jefferies Global Healthcare Conference in London - BOLT BIOTHERAPEUTICS INC
All right. Good morning, everyone. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have you all with us on this last morning of the Jefferies Global Healthcare Conference in London. Super excited to have Dr. Sheila Gujarati from Prana Therapies to introduce this new and exciting company. Great. Thank you so much. So pleased to be here and really talking about what we're doing at Prana therapies. I think, you know, really for the second time now in a public investor conference. So we started Prana Therapies to really develop the next generation of bispecific antibodies and multispecific long-acting therapies with the intention of developing best in disease therapeutics. So our, you Know, given my long history in immunology development for the last three decades, very familiar with many of the disease areas that we work in in the chronic immunology and inflammatory space. And as you know, many times we butt up against an efficacy ceiling that we see when we go after one target. We cycle through different mechanisms, but it's difficult for us to break through that efficacy ceiling. So I do think combinations of mechanisms is here, and it's a great way to improve upon clinical outcomes and break through the efficacy ceiling, And we think the best way to deliver combination therapy is through multi-specifics. And we set out to solve really delivering that multi-specific type platform. So that was the real intention of developing Prana Therapies. And through our diligent efforts to make sure we were addressing all the bi-specific challenges that we were seeing in the space, we actually created an entirely wholly owned platform at Prana called Inspire. So everything we do is internally designed. We have our own IP. We don't license technology or assets from China or other regions. We actually just develop things ourselves with a lot of expertise and discovery and development. Our lead program is PRA216. We actually set out to develop the best in disease therapy for respiratory indications, including asthma and COPD, as well as other atopic conditions that many of these patients suffer from, which I'm hoping to talk about more. And so PRA216 is going after IL-4 receptor alpha and T-slip because we think those are the best validated mechanisms to combine based on strong clinical and scientific rationale. Having said that, we knew we had to deliver a bispecific that would have infrequent dosing, excellent CMC, sub-Q formulations, really minimal immunogenicity, and long dosing intervals. And we've really delivered that for the optimal target profile with PRA 216. So really excited to tell you more about that program. We have a pipeline of multi-specifics behind 216 that we have yet to announce. So we're just getting started. We did a $120 million concurrent pipe financing when we did a reverse merger sign and close stock-for-stock transaction with Bolt about a month ago, I think, at this point. And so we're off to the races. We have runway into 2028, and we're really thrilled. We're going to have four Phase II data readouts next year. Asthma, COPD, atopic dermatitis, and eosinophilic esophagitis, a very exciting indication. So really thrilled. We have a lot of upcoming data catalysts in 2027. Okay, awesome. Thank you so much, Sheila. There's so much to dive into there. Maybe just one spot to start on. You mentioned the long history that you have in some of these type 2 inflammatory disorders. Can I just ask you, because you have really a wealth of kind of background in these areas, Can I ask you to elaborate on that just a little bit more and talk about what learnings you picked up along the way that led you to 216 and this idea of IL-4 receptor alpha with TSLP as really an optimal approach for some of these disorders? Yeah, thank you so much, Faisal. It's true. So I am a clinician. I train in internal medicine, and I trained in allergy immunology. So this is my clinical area of expertise. I've seen many patients with asthma and, of course, atopic dermatitis and a lot of patients who have several comorbid conditions at the same time. I'm really thrilled with all the development work we've done. I've been doing immunology drug development for the last three decades at Genentech, BMS, and also in multiple other small biotech companies as the chief medical officer. And I've really led development for many, many immunology programs, including Zoller. So we're very involved in launching Zolle. the first biologic in asthma. I've also worked extensively on IL-13 antibodies, touched labracuzumab and Genentech, but mainly we actually, when I was chief medical officer of Receptos, brought in an IL-15 program, syndicumab, where we ran the first IL-16 EOE study. So I'm going to talk a little bit about that too, hopefully. And really, no IL-14, no IL-4 receptor alpha, and these other disease mechanisms. So we have a lot of understanding of the unmet need that we're trying to address, up to 10% of severe asthma patients in the United States, which is up to ten percent of the entire asthma population, are inadequately controlled. It's even worse for COPD. And so there's a lot of unmanaged EOE. It's a very growing field, has been really underdiagnosed. So we have a real passion for this area, and we need to develop better therapies to get better control of these diseases over time. And also, if you don't control these diseases, these patients lose lung function. And I've seen so many patients who, with uncontrolled disease, really cannot even walk 10 feet. So that's really substantial. Hector Ortega, our chief medical officer, is really very well-versed in this area, also an allergist trained at the NIH. He was very involved with developing mepolizumab, the first anti-IL-5 therapy, and defined TH2 high disease, eosinophilic asthma. Also worked on LEBRI, IL-13, Genentech, and COPD and asthma for those failed studies. So, again, knows that space very well. and T-SLIP. So he's really touched upon a lot of the mechanisms that we know. And we come to this with a lot wealth of development experience. And again, our thesis is that you really want to hit the three targets, IL-4, IL13, and T SLIP, which we're delivering by targeting IL-1 receptor alpha and T SLEP in our bispecific. Got it. Awesome. I think that's super interesting context for the discussion. So I want to talk about the action and the biological hypothesis here i want to talk about your platform because it's super amazing and interesting that you've developed this in-house and then i want to talk about the uh the trials that you're running the indications especially eoe i think that's a underappreciated area but first just starting with the biology here right can you talk about how you see the value of hitting il4 and tslp and i think for a lot of investors you know where there might be a little bit confusion is whether there's redundancy here, that you're hitting one upstream, one downstream. Why would that be synergistic or beneficial? So can you talk about the hypothesis here of hitting both of these targets? Yes, no, absolutely. I do think there is some confusion. So both are very relevant targets. Now, remember, when we target IL-4 receptor alpha, which is the target for Dupixent, Dupizent is an $18 billion drug growing to $30 billion. It's approved in eight indications. It is the best TH2 blocker out there, really addressing all of the comorbid conditions in the atopic spectrum. And when you think about how to treat these patients, you're really thinking about the atomic march, because half to two-thirds of patients have comorbide conditions. So it's a very substantial thing to think about holistically when you think about the patient. So IL-4, again, goes after IL-3 and 13, and these have non-overlapping mechanisms. You really want to hit both IL-4 and 13 to get the best efficacy in respiratory asthma, COPD, and EOE. Now, T-slip is an excellent mechanism. It's an upstream epithelial cytokine alarming pathway. When you target T-Slip, you do affect downstream Th2 mechanisms and beyond T2. But there is a lot of data showing very distinct transcriptome analyses where you affect different genes. So while you do get reduction, especially in IL-5 and IL-13, when you're hitting T-slip, you actually don't hit IL-4 very well. So you really want to, again, hit upstream as well as the downstream effector arms for both IL-3 and IL 13 to get the best efficacy. And now there are case reports of dupy failures responding to T-SLIP. And as you know, T-Slip does not work very effectively in atopic dermatitis. So these are not, you know I think there's not complete redundancy here, I think just by targeting both, we're going to get the breadth of immune suppression that we need to see and the depth of response that we're hoping to really improve upon. Got it. And when you were talking about your background, you mentioned that you and others on the team like Hector have direct experience with IL-13 development as well, yet with 216, you've very deliberately chosen to do an IL-4 receptor alpha-based approach. Can you talk a little bit more about how and why you see the advantages of IL-4 compared to IL-13? Yeah, so IL-5 receptor alpha is not a trivial target. It's a receptor target that's expressed in high quantities on different cell types. It has target-mediated drug disposition. So I think you've seen a lot of companies and individuals go after IL-15 containing five specifics. But from our perspective, that really isn't the right biology. So we set out to actually address this challenge of not only how to get extended half-life extended IL-4 receptor alpha, but how to do it in a bispecific, which is even more challenging. And we really cracked that nut. So we're so thrilled to see our data. But IL-5 is so central to the Th2 cytokine pathway, to the TH2 pathway. It's involved with the differentiation of naive cells, the Th3 phenotype, amplification of that cascade, and IgE class switching. None of those are affected when you hit IL-13. So that's why you want to hit both IL-4 and 13, but really the proof in the pudding is looking at the clinical data. There have been multiple IL-3 trials run in asthma and COPD, and, of course, I ran one in EOE and receptose. We do see modest efficacy with basically IL-14 blockers in these indications, but it doesn't come close to what you see with IL-1 receptor alpha in these areas. For syndicumab, we had a 30% histologic remission rate. DUPI doubled that at 60%. Actually, I was very excited to see the IL-13 data, but then when I saw the DUPi data, I knew it wasn't going to have enough efficacy. Similarly, in asthma, you see some phenoimprovement and FEV1 improvement. However, that has not translated into exacerbation improvement, which is really getting control of asthma attacks. And so DUPи has much better improvement there. And in COPD, that was a failed study that Genentech ran with lebrecuzumab. It was a 300-patient study and actually didn't show any improvement in exacerbations and very minimal improvement in FEV1. So there's a lot of clinical data when you look at the large Phase II and III trials that have been conducted, which have shown IL-13s failing and not having consistent efficacy and really not the right approach if you want to develop best-in-disease efficacy. Got it. So, Sheila, I think what I'm going to ask next I think personally is the most critical question that I'm going to ask you today. So I think from the outside in, right, so I know you've been working on this Inspire platform for a number of years now. From the investor perspective, kind of looking at this space, there's this sense of, oh, man, there's a lot of these bispecifics hitting these type 2 inflammatory targets. How do I differentiate between these different things that are here both from a target pairing perspective but then also from an antibody design and engineering perspective? So can you talk to us about the kind of learnings that you guys have picked up on from your years of work trying to develop these bispecifics and then also why you see your platform and this asset specifically as differentiated from the other approaches? So not all bispecifics are created equal. I think we've learned a lot about half-life extension technology for monospecific antibodies, and I think that is getting more commoditized. We know how to do that. Many companies can do that, this has really been a challenge for bispecifics. So for us, the key aspects of developing a best-in-disease therapy, which we have done with PRA216, we think, is going after the right targets based on the biologic and scientific rationale. But beyond that, to your point, Faisal, it's going afterthe right format that's going to deliver the right exposure to be able to neutralize and cover those targets throughout your extended dosing interval. So this is a really key principle that I think maybe is lost amongst, you know, individuals when looking at this competitive landscape. And so we spent years trying to understand what is that construct and format that's going to give us that extended dosing interval very robustly so we can cover those targets to deliver best in disease efficacy. So we spent, actually we integrated a number of different constructs in all different positions, and we came upon our novel format and platform, we are fully human, fully IgG platform, which really has improved upon YTE. So we incorporate YTE mutations, but we go beyond YTE, so we're YTE plus, because the way we've designed our construct, it's so stable that when these antibodies go through FTR and recycling, many of them break apart. They're not stable. these VHH, SCFV, they don't really survive that acidic endosomal recycling process. The Prana platform does. The Inspire platform does, and then this is how we see that really extended PK because you, again, need to make sure you're having high exposures throughout the dosing interval, and when you're trying to go to Q8 weeks or Q12-week dosing, which is our target profile here, you, Again, want to hit the target throughout that dosing integral. So we haven't seen any bispecific going after our target pair, IO4-sept or alpha-T-sep, that can deliver that. And I think that's critical, and we know that when we go after even cytokine bispecifix and trispecifics, we're going to have even better PK. So we're just thrilled with our data. So think about Inspire platform is to bispecitics, but YTE and Half-Life Extension is to monospecifics. That's the improvement that we've made that we think is so novel, and we've already had our IP granted. Got it. I think that's a really interesting point because, you know, for those of us that aren't engineering antibodies, I think there's a perception of, okay, you can just introduce the YTE mutation, and that gets the job done. But as you're saying, that might be true for some targets. It might be truth for monospecifics, but not necessarily across the board. Yeah, when you look at most of the bispecific out there that are in the clinic, they actually have worse PK to DUPI. So, you know, I think it's really important to take a close look at the PK, the half-life, the exposure, really, even more than half-Life, because TMDD is difficult to interpret half- Life. But you've got to look at exposure throughout the dosing intervals. So you want to see that population PK analysis and make sure you're neutralizing the target. And when you do that, you quickly see that most of the programs out there are not covering the target, and we do. So we spent a lot of time educating about looking at those exposure models, not only through the induction period, because we can all dose high initially, but through the maintenance period. You want to see, again, sustained PK exposure really for the duration of treatment, because these patients are going to be on this therapy for years. Yeah. And then I think the other thing that's important to mention here is that this is not just theory, right? This is not juste kind of preclinical data. You have some interesting phase one data as well. So can you talk just a little bit about the Phase I data and what parts of that Phase I data show you that you're differentiated from others who are trying to do this? So we did a robust Phase I normal healthy bond tier study looking at single ascending dose cohorts and multiple ascending dose cohords with both sub-Q and IV formulation. So we have really an excellent sub-q, high concentration, low viscosity formulation. And in that Phase 1, we saw excellent PK and exposure, which I'm going to talk about. We also saw robust PD biomarker reduction, which was best in disease, again, better than what we saw with other monospecific and other combinations of other bispecifics. And we saw great safety and tolerability. So we had no injection site reactions, no cases of local pain. We had minimal immunogenicity. And, again. A lot of other companies don't report out their immunogenicities data. We had only one patient who had low titer ADA coming out of our phase one at a late time point that was not neutralizing. So we're really thrilled with our immunogenicity profile, which is validating for our fully human, fully IgG approach. Our PK was truly, you know, best in class. We've actually compared our PK curves directly to other competitors out there, and we are significantly better on a log scale. You can see that. We'd be happy to share that in our corporate presentation on the BOLT website for you to look at, and we can share that data with you, direct head-to-head comparison. We have 85% subcube bioavailability. And after single IV doses, we have PK exposure out to 16 weeks after multiple sending doses, which we study three doses in a one-month interval at week zero, two, and four. We have PK exposures above the EC90 greater than 20 weeks. So really exciting data and really supporting our every eight-week or every 12-week dosing. And from that, we did thorough population PK modeling. When you are running a biologics program, the most PK data you get is from your phase one trial. You can take that and actually do extensive population PK modeling to show what you're going to do over the time. And so we've actually done that to show our robust PK exposure. So we have best-in-class PK compared to the other therapies out there. We have a half-life, it's difficult to report half-lifes, but if you look at our linear half-like that clinically relevant exposures, we are at 50 days. And you have to ask, again, around what is the population PK analysis-derived numbers. And then furthermore, we have 50 percent TARC reduction. We have about near 100 percent eosinophil reduction and robust IgE reduction. So again, best-in-class PDE reduction as well. Male Speaker 1 Got it. And then I want to come to the trials, and I think something that's important for people to appreciate is that you're actually quite advanced in this field. You have three Phase IIs that are in flight across asthma, COPD, and atopic derm. And I know you just became a publicly traded entity, but you guys have been, you know, building behind the scenes for a while. But I actually want to talk about the Phase II that you're getting started now in EOE. Can you talk to us about the sort of level of evidence for IL-4, IL-13, and for TSLP in EoE, and where you see the unmet need and opportunity here? Yes, eosinophilic esophagitis has become a really highly prioritized indication for us. We were always excited about EOE. It's a growing area. DUPI is going to be doing $2 billion in sales just in EOEs alone, and the prevalence has grown five times since 2009. So, again, it's been an underdiagnosed disease, so we have to address that unmet need. So we were always exciting about IO4-ceptor alpha, as I mentioned, very substantial efficacy looking at histologic remission as well as dysphagia improvement. This is difficulty swallowing, which is a key unmet need you want to address. DUPI has to go to pretty high doses. They have to be weekly dosing. So we know that we can deliver the increased exposure to actually get after target neutralization. So when TESPIRE read out recent positive data in EOE, we were thrilled. Now we have independent clinical validation for both these targets that we're going after, and also Uniquity Bio just read out recently positive data. So there's data now supporting IO4 receptor alpha and T-SLIB. So combining this, and there's case reports, again, where patients are responding to one mechanism and not another. So we are thrilled. We think we can improve histologic remission. We think мы can improve the dysphagia scoring symptoms for these patients. So we're doing a Phase II trial. The goal is to have that Phase II trail read out next year in the second half of 2027, where we're going to look to have improved efficacy while still delivering improved dosing regimens over DUPI and TESPIRE. So we're really thrilled. We think we can have a best-in-disease therapy for EOE, which, again, is still very underserved at this time. Got it. And then, so this adds a fourth phase two catalyst for next year. So you also have COPD, asthma, and atopic derm. Can you just kind of educate us on, just briefly, on, like, the trial design and also just the cadence or sequence of these readouts? Yes. So we think asthma will be reading out first, potentially in Q2. The rest of the data readouts will be in the second half of 2027, and we'll be guiding more on the timing of the data readout as we get, you know, continue to get these trials enrolled. They're all enrolling at this point. Those three trials and EOE is about to get off the ground. So, you know, what we're looking for is to see the totality of the data looking across these four disease areas, but we're looking for asthma, we're looking at FENO, FEV1, biomarker improvement. We're also looking at small airway disease. So we're really looking to see robust improvements in those endpoints. For COPD, also similar endpoints, but we're also looking at mucus plugs for CT scans, a nice objective endpoint, which we think will have some really great data on. We're well-powered to look at the improvement in mucus plug. For AD, we'll look at EC scores, especially EC75 placebo-adjusted scores, as well as, and then EOE, we will look at histologic remission and DSQ, dysphagia symptom improvements. We have robust placebo control arms in each of these trials. There are about 40 patients in size for each trial. So I think we're going to have, again, a nice set of robust data readouts. And our plan is to go into phase three starting in 2028. So we are on an accelerated development trajectory. We've had an FDA discussion on our development path and general agreement. So we're really racing forward. We like to execute quickly and with high quality. Yeah, and I think what's interesting, I mean, coming back to really the start of the discussion, You spoke about your background doing drug development and Genentech, and I think what's notable here is the trial portfolio that you've built enables that broadly staged development in a rapid time frame. So I know we're coming on time. One thing I wanted to address briefly as well is there is another IL-4 receptor alpha T-slip program out there that has shown some early stage data. I just want to understand from that data set from the competitor, where do you see kind of validation of the idea that you're pursuing? And where do you see your opportunity to really come in and be a step better? Yeah, so as I've mentioned, there are some other IL-4 receptor alpha T-slip programs out there. And to talk about the one you're referring to, they recently reported data on atopic dermatitis and asthma. And we actually think it's like a perfect Goldilocks scenario for us. Because if you look at their data, and again, this is, I think, we do think there are some exposure challenges with that format and construct. But they actually saw pretty robust data at day 15, which is, and then they originally got it to day 29 readouts, but you see a drop-off in efficacy at day 29 when I think their exposure is dropping. Again, further validating, they were going after the right targets and the right exposure levels with our approach, because you want to see that durable exposure coverage and efficacy. But if you look at their day 15 they saw a really nice substantial improvement in FEV1, robust reduction in pheno, and improvements in other biomarkers. And so we're really thrilled that we think that our thesis is being validated. And the EC90 levels that we're targeting that have been established by Dupixent and tezopilimab and Tezpire are really the right thresholds we need to cover. So we're going after EC90 clinical targets with our therapy, and I think that's going to really lead to robust efficacy. So we think it's very clinically validating for what we're trying to do in asthma and atopic dermatitis. They had about a 45% EC75 placebo-adjusted improvement. You want to be in that range for a best-in-disease therapy. Also, Pfizer to recommend data, deliver data in that range, and that's important when you look at the topic spectrum. So we're thrilled because we think they're clinically validating what we're talking about, but they don't have the construct and the exposure, and I don't believe they're going forward in respiratory. So I think we're pretty thrilled that we're going to be, you know, set up for success. Got it. So, Sheila, you've described Prana as right target, at right exposure, right format. I think you've kind of educated us really nicely on a lot of that. I think the thing I would add from the investor angle is right catalyst path as well given how exciting 2027 will be for you. So thank you so much for being here. I just want to pass it back to you for any closing remarks you have. Well, we're just getting started. We have a second program, which is an IL-31 containing bispecific that we're moving into the clinic for high-itch atopic dermatitis. Our goal is to have some clinical data by the end of next year. So we're really excited about that program as well. We think it's going to be a great complement to 216. And then we are going to move at least two other programs forward closer to the clinic from our Inspire platform in really high-relevant disease areas where combination therapies and other mechanisms have been validated. So, again, we're just getting started. We've designed actually over 120 programs internally. So we are really thrilled with what we can achieve alone here at Prana. And I do agree, we are thrilled to have the financing now to see us through all four Phase II data catalysts next year and beyond. So thank you so much, Faisal. Awesome. Thank you for being here. Thank you to the audience as well.
- Company
- BOLT BIOTHERAPEUTICS INC
- Keywords
- BOLT BIOTHERAPEUTICS INC